Physician
GML Pain MD PSC
GML Pain MD PSC was paid $3.90M by Medicaid between Jan 2018 and Dec 2024, across 31 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 38% of everything it billed.
33Billing provider infoGML PAIN MD PSC
LOUISVILLE, KY 40241
LOUISVILLE, KY 40241
33aNPI1396120820assigned 07/27/2015
33bProvider typeInterventional Pain Medicine Physician
28Total paid$3.90M
24GClaims115,429
24DCodes billed31
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Kentucky
Rank by total paid#2 of 24
Median peer was paid$58K
This provider vs. median67×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,908 | $301K | |
| 2019 | 14,340 | $538K | |
| 2020 | 23,837 | $899K | |
| 2021 | 26,129 | $915K | |
| 2022 | 16,592 | $437K | |
| 2023 | 15,047 | $429K | |
| 2024incomplete | 10,576 | $385K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 38% | 33,801 | 26,373 | $1.47M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 23% | 31,544 | 26,653 | $915K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 14% | 11,683 | 10,363 | $549K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 7.9% | 3,870 | 3,360 | $308K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 7.3% | 14,550 | 12,873 | $284K |
| 62323 | 3.2% | 1,043 | 948 | $125K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.7% | 6,124 | 5,606 | $66K |
| 99406 | <1% | 4,012 | 3,683 | $32K | |
| 99408 | <1% | 1,581 | 1,398 | $25K | |
| 90791 | Psychiatric diagnostic evaluationPsychiatric diagnostic evaluation | <1% | 322 | 312 | $21K |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 1,743 | 1,469 | $17K |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | <1% | 523 | 406 | $16K |
19 more codes
| 20610 | <1% | 267 | $12K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 706 | $12K |
| 77002 | <1% | 273 | $10K | |
| 97151 | <1% | 243 | $7K | |
| 64493 | <1% | 60 | $6K | |
| 90837 | Psychotherapy session, about an hour | <1% | 75 | $5K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 445 | $4K |
| 64635 | <1% | 13 | $3K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 749 | $3K |
| 64494 | <1% | 46 | $3K | |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 895 | $2K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 610 | $2K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 29 | $2K |
| 64636 | <1% | 14 | $1K | |
| 20553 | <1% | 33 | $1K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 118 | $1K |
| 90838 | <1% | 24 | $961.77 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 18 | $316.30 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 15 | $246.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJACKSON, JEFFERNIKA (PRACTICE MANAGER)